Inducing and exploiting vulnerabilities for the treatment of liver cancer
Cun Wang,
Serena Vegna,
Haojie Jin,
Bente Benedict,
Cor Lieftink,
Christel Ramirez,
Rodrigo Leite Oliveira,
Ben Morris,
Jules Gadiot,
Wei Wang,
Aimée Chatinier,
Liqin Wang,
Dongmei Gao,
Bastiaan Evers,
Guangzhi Jin,
Zheng Xue,
Arnout Schepers,
Fleur Jochems,
Antonio Mulero Sanchez,
Sara Mainardi,
Hein Riele,
Roderick L. Beijersbergen,
Wenxin Qin (),
Leila Akkari () and
René Bernards ()
Additional contact information
Cun Wang: Shanghai Jiao Tong University School of Medicine
Serena Vegna: The Netherlands Cancer Institute
Haojie Jin: Shanghai Jiao Tong University School of Medicine
Bente Benedict: The Netherlands Cancer Institute
Cor Lieftink: The Netherlands Cancer Institute
Christel Ramirez: The Netherlands Cancer Institute
Rodrigo Leite Oliveira: The Netherlands Cancer Institute
Ben Morris: The Netherlands Cancer Institute
Jules Gadiot: The Netherlands Cancer Institute
Wei Wang: The Netherlands Cancer Institute
Aimée Chatinier: The Netherlands Cancer Institute
Liqin Wang: The Netherlands Cancer Institute
Dongmei Gao: Ministry of Education
Bastiaan Evers: The Netherlands Cancer Institute
Guangzhi Jin: Second Military Medical University
Zheng Xue: The Netherlands Cancer Institute
Arnout Schepers: The Netherlands Cancer Institute
Fleur Jochems: The Netherlands Cancer Institute
Antonio Mulero Sanchez: The Netherlands Cancer Institute
Sara Mainardi: The Netherlands Cancer Institute
Hein Riele: The Netherlands Cancer Institute
Roderick L. Beijersbergen: The Netherlands Cancer Institute
Wenxin Qin: Shanghai Jiao Tong University School of Medicine
Leila Akkari: The Netherlands Cancer Institute
René Bernards: The Netherlands Cancer Institute
Nature, 2019, vol. 574, issue 7777, 268-272
Abstract:
Abstract Liver cancer remains difficult to treat, owing to a paucity of drugs that target critical dependencies1,2; broad-spectrum kinase inhibitors such as sorafenib provide only a modest benefit to patients with hepatocellular carcinoma3. The induction of senescence may represent a strategy for the treatment of cancer, especially when combined with a second drug that selectively eliminates senescent cancer cells (senolysis)4,5. Here, using a kinome-focused genetic screen, we show that pharmacological inhibition of the DNA-replication kinase CDC7 induces senescence selectively in liver cancer cells with mutations in TP53. A follow-up chemical screen identified the antidepressant sertraline as an agent that kills hepatocellular carcinoma cells that have been rendered senescent by inhibition of CDC7. Sertraline suppressed mTOR signalling, and selective drugs that target this pathway were highly effective in causing the apoptotic cell death of hepatocellular carcinoma cells treated with a CDC7 inhibitor. The feedback reactivation of mTOR signalling after its inhibition6 is blocked in cells that have been treated with a CDC7 inhibitor, which leads to the sustained inhibition of mTOR and cell death. Using multiple in vivo mouse models of liver cancer, we show that treatment with combined inhibition of of CDC7 and mTOR results in a marked reduction of tumour growth. Our data indicate that exploiting an induced vulnerability could be an effective treatment for liver cancer.
Date: 2019
References: Add references at CitEc
Citations: View citations in EconPapers (3)
Downloads: (external link)
https://www.nature.com/articles/s41586-019-1607-3 Abstract (text/html)
Access to the full text of the articles in this series is restricted.
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:574:y:2019:i:7777:d:10.1038_s41586-019-1607-3
Ordering information: This journal article can be ordered from
https://www.nature.com/
DOI: 10.1038/s41586-019-1607-3
Access Statistics for this article
Nature is currently edited by Magdalena Skipper
More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().